Visual neuroprostheses, including retinal and cortical implants (commonly known as “bionic eyes”), have shown promise as assistive technology for individuals with blindness.
1–7 These devices, similar to cochlear implants, electrically stimulate remaining neurons in the visual pathway to evoke visual percepts (
phosphenes).
8,9 Existing devices have demonstrated improved capabilities in localizing high-contrast objects and aiding basic orientation and mobility tasks.
4,10 Notable examples include Argus II
1 (Second Sight Medical Products, Inc., Sylmar, CA, USA), the first retinal implant to obtain US Food and Drug Administration (FDA) approval, and its successor, Orion
7 (Cortigent, Valencia, CA, USA; formerly Second Sight), a cortical implant that is currently in clinical trials (clinicaltrials.gov: NCT03344848). In addition to neuroprostheses, other promising avenues for sight restoration include optogenetic, gene, and stem cell therapies,
11–14 which offer less invasive alternatives by targeting the genetic and molecular bases of visual impairment.
The Argus II utilizes a 6 × 10 electrode array implanted on the retina, which receives signals from a camera mounted on glasses to provide visual information (
Figs. A, B). Additionally, the efficacy of the Argus II device is primarily contingent upon the condition of the retina and the electrode–retina distance.
15–18 Some stimulation parameters may enhance the device's effectiveness, while other factors (e.g., inadvertent activation of passing axon fibers) impose limitations on its performance.
17,19,20 In contrast, the Orion device bypasses the eye altogether, with electrodes implanted directly on the surface of the visual cortex, aiming to restore vision by stimulating the brain's visual processing areas (
Fig. C). The effectiveness of the Orion varies based on stimulation and neuroanatomical parameters
7,21 (e.g., amplitude, location, timing). The Argus II has been implanted in 388 recipients worldwide, both commercially and during clinical trials (157 female and 231 male; personal communication with Cortigent, Inc., 2024). The Orion device, still in clinical trials, has been implanted in six recipients (one female and five males), with three remaining implanted to date. There is a notable distinction between clinical trial participants and commercial users regarding selection, training, and ongoing support. Clinical trial volunteers are meticulously selected, receive extensive training, and regularly visit the lab, providing critical feedback for future device iterations. In contrast, commercial users typically receive assistance from third-party companies or centers, often at their own motivation, with less rigorous selection and training protocols, although some may still elect to participate in related research and experiments.
Research in artificial vision has traditionally followed the medical model of disability,
23 viewing blindness as a result of an individual's physical impairment that can be “fixed”—in this case, with an invasive prosthesis. As pointed out by other studies,
24–26 most research on visual prostheses (and, more generally, low vision aids) has primarily focused on technological and functional aspects of these implants (e.g., the ability to produce phosphenes and the resulting Snellen acuity) and has rarely incorporated implant recipients (
implantees) in the decision-making and design process.
26 However, blindness is not just about one's physical impairment but also about the individual's subjective psychological experience and the societal contexts in which they live.
27,28 In the development and evaluation of assistive technologies for people who are blind, it is crucial to focus not only on the technical aspects but also on the wants, needs, and lived experiences of the end users, studying how they might utilize such devices within their daily lives. This approach ensures that technology serves the user, enhancing their quality of life rather than solely aiming to correct a physical condition.
Although tools and surveys have been developed to assess the functional visual ability and well-being of implantees,
10,29–31 in practice, these are often employed as external validation tools that constitute the very last step of the design process.
44,29 It is therefore perhaps not surprising that none of the current devices have found broad adoption and that several device manufacturers had to close their doors because their device did not (such as in the case of Retina Implant AG) lead to “the concrete benefit in everyday life of those affected” (
https://web.archive.org/web/20200805082212/https://www.retina-implant.de/en).
This lack of end-user involvement and limited adoption underscores the necessity for a deeper exploration into how implants are actually used in daily life, contrasted with the initial expectations of their designers. Despite numerous studies assessing functional vision
4,6,29 and documenting the experiences of current implantees,
10,25,32,33 as well as discussions on ethical considerations in trial participant selection
34,35 and the attitudes of blind individuals toward implant technology,
36 a comprehensive understanding of the real-world application of these devices remains elusive.
This retrospective qualitative study aims to explore the perspectives, experiences, practices, and aspirations of individuals who have received one of the most commonly available visual implants (Argus II or Orion). It also seeks to contrast these user insights with the viewpoints of prominent researchers who are either involved in developing these devices or interact directly with the implantees. We also sought feedback from implantees to identify current technology limitations and gather suggestions for future enhancements. Through reconciling the viewpoints of both researchers and implantees as well as fostering cooperative efforts in the design process, we hope that the next generation of visual prosthetic technology can have a profound impact on the quality of life of millions of people worldwide.